Pure recombinant enzyme
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Citrullinated α-Enolase (human, recombinant)

Item No. 21585

Technical Information
Synonyms
  • Enolase-1
Purity
≥90% estimated by SDS-PAGE
Source
Recombinant enolase expressed in E. coli citrullinated by PAD4
Amino Acids
1-434 (full length)
MW
47.74 kDa
TBS, pH 7.4
UniProt Accession №
P06733
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Product Description

    α-Enolase, also known as enolase-1, is a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate.1 It is ubiquitously expressed in human tissues, including liver, spleen, kidney, and brain. In cells, α-enolase is primarily localized to the cytoplasm, however, an alternatively translated form localizes to the nucleus and lacks glycolytic enzyme activity.1,2 α-Enolase functions as a cell surface receptor for plasminogen on pathogens and activated immune cells, as an oxidative stress protein in endothelial cells, and as a chromatin binding partner to facilitate transcription.2,3,4 It is an autoantigen in asthma, Hashimoto's encephalopathy, and rheumatoid arthritis, and has been found in the serum of pediatric patients with juvenile idiopathic arthritis.5,6,7,8 α-Enolase is also subject to citrullination by peptidyl arginine deiminases (PADs) and citrullinated α-enolase has been found in the synovial fluid of rheumatoid arthritis patients.7

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Zhu, X., Miao, X., Wu, Y., et alENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in non-Hodgkin’s lymphomas. Exp. Cell Res. 335(2), 216-223 (2015).

    2. Song, Y., Luo, Q., Long, H., et alAlpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol. Cancer 13, 65 (2014).

    3. Subramanian, A., and Miller, D.M. Structural analysis of α-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. The Journal of Biological Chemisty 275(8), 5958-5965 (2000).

    4. Hsiao, K.-C., Shih, N.-Y., Fang, H.-L., et alSurface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target. PLoS One 8(7), e69354 (2013).

    5. Nahm, D.-H., Lee, K.-H., Shin, J.-Y., et alIdentification of α-enolase as an autoantigen associated with severe asthma. J. Allergy Clin. Immunol. 118(2), 376-381 (2006).

    6. Moore, T.L., Gillian, B.E., Crespo-Pagnussat, S., et alMeasurement and evaluation of isotypes of anti-citrullinated fibrinogen and anti-citrullinated α-enolase antibodies in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 32(5), 740-746 (2014).

    7. Yoneda, M., Fujii, A., Ito, A., et alHigh prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto’s encephalopathy. J. Neuroimmunol. 185(1-2), 195-200 (2007).

    8. Cong, Y., Wang, L., Peng, R., et alTimosaponin AIII induces antiplatelet and antithrombotic activity via Gq-mediated signaling by the thromboxane A2 receptor. Sci. Rep. 6, 38757 (2016).

    Product Citations

    Moon, J.-S., Younis, S., Ramadoss, N.S., et alCytotoxic CD8+ T cells target citrullinated antigens in rheumatoid arthritis. Nat. Commun. 14(1), 319 (2023).